share_log

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Benzinga ·  Apr 30 09:01

In the last three months, 5 analysts have published ratings on Deciphera Pharmaceuticals (NASDAQ:DCPH), offering a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings10400
Last 30D00100
1M Ago00200
2M Ago00100
3M Ago10000

In the assessment of 12-month price targets, analysts unveil insights for Deciphera Pharmaceuticals, presenting an average target of $23.24, a high estimate of $26.00, and a low estimate of $16.00. Observing a 30.93% increase, the current average has risen from the previous average price target of $17.75.

price target chart

Understanding Analyst Ratings: A Comprehensive Breakdown

The perception of Deciphera Pharmaceuticals by...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment